182 related articles for article (PubMed ID: 17152347)
41. Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.
Li C; Choi DH; Choi JS
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):99-108. PubMed ID: 22210483
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
Ridtitid W; Ratsamemonthon K; Mahatthanatrakul W; Wongnawa M
J Clin Pharm Ther; 2007 Dec; 32(6):585-93. PubMed ID: 18021336
[TBL] [Abstract][Full Text] [Related]
43. Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs.
Van der Heyden S; Croubels S; Gadeyne C; Ducatelle R; Daminet S; Murua Escobar H; Sterenczak K; Polis I; Schauvliege S; Hesta M; Chiers K
Am J Vet Res; 2012 Jun; 73(6):900-7. PubMed ID: 22620706
[TBL] [Abstract][Full Text] [Related]
44. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
Miller AK; DiCicco RA; Freed MI
Clin Ther; 2002 Jul; 24(7):1062-71. PubMed ID: 12182252
[TBL] [Abstract][Full Text] [Related]
45. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
Saitoh H; Aungst BJ
Pharm Res; 1995 Sep; 12(9):1304-10. PubMed ID: 8570526
[TBL] [Abstract][Full Text] [Related]
46. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
Kharasch ED; Hoffer C; Whittington D
Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
[TBL] [Abstract][Full Text] [Related]
47. The use of formulation technology to assess regional gastrointestinal drug absorption in humans.
Basit AW; Podczeck F; Newton JM; Waddington WA; Ell PJ; Lacey LF
Eur J Pharm Sci; 2004 Feb; 21(2-3):179-89. PubMed ID: 14757489
[TBL] [Abstract][Full Text] [Related]
48. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
49. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system.
Nakayama A; Saitoh H; Oda M; Takada M; Aungst BJ
Eur J Pharm Sci; 2000 Oct; 11(4):317-24. PubMed ID: 11033075
[TBL] [Abstract][Full Text] [Related]
50. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada SK; Yellu NR; Neerati P
Pharmacol Rep; 2016 Apr; 68(2):338-43. PubMed ID: 26922536
[TBL] [Abstract][Full Text] [Related]
51. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.
Ashiru DA; Patel R; Basit AW
Pharm Res; 2008 Oct; 25(10):2327-33. PubMed ID: 18600434
[TBL] [Abstract][Full Text] [Related]
52. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans.
Parker RB; Yates CR; Soberman JE; Laizure SC
Pharmacotherapy; 2003 Aug; 23(8):979-87. PubMed ID: 12921244
[TBL] [Abstract][Full Text] [Related]
53. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
Zhou X; Gao ZW; Meng J; Chen XY; Zhong DF
Acta Pharmacol Sin; 2013 Nov; 34(11):1420-6. PubMed ID: 24056704
[TBL] [Abstract][Full Text] [Related]
54. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Bolton AE; Peng B; Hubert M; Krebs-Brown A; Capdeville R; Keller U; Seiberling M
Cancer Chemother Pharmacol; 2004 Feb; 53(2):102-6. PubMed ID: 14605865
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.
Sekar VJ; Lefebvre E; De Paepe E; De Marez T; De Pauw M; Parys W; Hoetelmans RM
Antimicrob Agents Chemother; 2007 Mar; 51(3):958-61. PubMed ID: 17210768
[TBL] [Abstract][Full Text] [Related]
56. Inhibitory effect of ketoconazole on the pharmacokinetics of a multireceptor tyrosine kinase inhibitor BMS-690514 in healthy participants: assessing the mechanism of the interaction with physiologically-based pharmacokinetic simulations.
Yang Z; Vakkalagadda B; Shen G; Ahlers CM; Has T; Christopher LJ; Kurland JF; Roongta V; Masson E; Zhang S
J Clin Pharmacol; 2013 Feb; 53(2):217-27. PubMed ID: 23436267
[TBL] [Abstract][Full Text] [Related]
57. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats.
Sandström R; Lennernäs H
Drug Metab Dispos; 1999 Aug; 27(8):951-5. PubMed ID: 10421625
[TBL] [Abstract][Full Text] [Related]
58. Comparative bioavailability of two tablet formulations of ranitidine hydrochloride in healthy volunteers.
Bawazir SA; Gouda MW; El-Sayed YM; Al-Khamis KI; Al-Yamani MJ; Niazy EM; Al-Rashood KA
Int J Clin Pharmacol Ther; 1998 May; 36(5):270-4. PubMed ID: 9629991
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic interactions between NSAIDs (indomethacin or sulindac) and H2-receptor antagonists (cimetidine or ranitidine) in human volunteers.
Delhotal-Landes B; Flouvat B; Liote F; Abel L; Meyer P; Vinceneux P; Carbon C
Clin Pharmacol Ther; 1988 Oct; 44(4):442-52. PubMed ID: 2901930
[TBL] [Abstract][Full Text] [Related]
60. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
